0
E-MAIL THIS PAGE  |  PRINT THIS PAGE
Information for Healthcare Professionals
Efficacy

Significantly Fewer Panic Attacks by Week 1

In One Study: Reductions in Panic Attack Frequency at Week 1

In One Study: Reductions in Panic Attack Frequency at Week 1
Randomized, multicenter, double-blind 6-wk trial of XANAX XR (n=62) vs placebo (n=62) or XANAX(n=67) in patients with panic disorder, with or without agoraphobia (DSM-III-R™). At Wk 6, neither XANAX XR nor XANAX were significant vs placebo. Dosage—XANAX XR and XANAX groups initiated at 1 mg/d and titrated upward as needed and tolerated to a maximum permissible dose of 10 mg/d. Mean dose of XANAX XR at last treatment visit: 4.6 mg/d.

In a Separate, 6-week Clinical Trial
70% of Patients Were Panic Attack-Free by Week 6

Percentage of Patients Panic Attack-Free at Endpoint

Percentage of Patients Panic Attack-Free at Endpoint


Randomized, multicenter, double-blind 6-wk trial of XANAX XR (n=104) vs placebo (n=95) in patients with panic disorder, with or without agoraphobia (DSM-III™). Dosage—1 mg/d, administered AM, and titrated upward as needed and tolerated to maximum permissible dose of 10 mg/d. Mean dose at last treatment visit: 4.2 mg/d. Analysis—LOCF (last observation carried forward) at each time point. At endpoint, 45% of patients taking placebo were panic attack–free.

  • In the first clinical trial presented above, efficacy of XANAX XR in achieving freedom from panic attacks was not statistically significant vs placebo at endpoint (Week 6)6,7
  • Treatment with XANAX XR should be initiated at 0.5 mg or 1 mg once daily; titrate in increments of no more than 1 mg/day in 3- to 4-day intervals

Tolerability & Safety >>

Important Safety Information: XANAX XR is contraindicated in patients with known sensitivity to this drug or other benzodiazepines, in patients with acute narrow-angle glaucoma, and in patients taking potent CYP3A inhibitors, such as ketoconazole and itraconazole.

Certain adverse clinical events are a direct consequence of physical dependence to alprazolam. These include a spectrum of discontinuation symptoms, the most important being the possibility of seizure.

The most commonly observed adverse events in patients treated with XANAX XR in controlled clinical trials (≥5% and at least twice the incidence observed for placebo) were: sedation (45.2% vs 22.6%), somnolence (23.0% vs 6.0%), memory impairment (15.4% vs 6.9%), dysarthria (10.9% vs 2.6%), abnormal coordination (9.4% vs 0.9%), ataxia (7.2% vs 3.2%), and decreased libido (6.0% vs 2.3%).

Please see full prescribing information for more information.


Privacy Policy    Terms of Use    Contact Pfizer

XN141121B © 2006 Pfizer Inc. All rights reserved.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.